Cost-Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation in Portugal

INTRODUCTION AND OBJECTIVES:Recently, three novel non-vitamin K antagonist oral anticoagulants received approval for reimbursement in Portugal for patients with non-valvular atrial fibrillation (AF). It is therefore important to evaluate the relative cost-effectiveness of these new oral anticoagulan...

ver descrição completa

Detalhes bibliográficos
Autor principal: Costa, J (author)
Outros Autores: Fiorentino, F (author), Caldeira, D (author), Inês, M (author), Lopes Pereira, C (author), Pinheiro, L (author), Vaz-Carneiro, A (author), Borges, M (author), Gouveia, M (author)
Formato: article
Idioma:eng
Publicado em: 2015
Assuntos:
CHLC FAR
Anticoagulants/therapeutic use
Atrial Fibrillation/drug therapy
Benzimidazoles/economics
Benzimidazoles/therapeutic use
Cost-Benefit Analysis
Dabigatran/economics
Dabigatran/therapeutic use
Pyrazoles/economics
Portugal
Pyrazoles/therapeutic use
Pyridones/economics
Pyridones/therapeutic use
Stroke/drug therapy
Warfarin/therapeutic use
Texto completo:http://hdl.handle.net/10400.17/2356
País:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/2356

Texto Completo

http://hdl.handle.net/10400.17/2356

Registros relacionados